Evidence map›Paper›PMID 40190686›Full record

ReviewAdvanced pharmaceutical bulletin2024

Energy-Based Methods and Nanocarrier-Based Approaches for Melasma Treatment.

Amiremad Kheirieh, Amirhessam Kheirieh, Zahra Mahdavi, Ali Mohammad Halvani, Amir Mohammad Bagheri, Hooriyeh Nassirli, Shiva Golmohammadzadeh, Bizhan Malaekeh-Nikouei

Abstract readReview
In one paragraph

Review in Advanced pharmaceutical bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Amiremad KheiriehDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0003-2409-3865
Amirhessam KheiriehClinical Research Development Unit, Bahar Hospital, Shahroud University of Medical Sciences, Shahroud, Iran.
Zahra MahdaviStudent Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Ali Mohammad HalvaniStudent Research Committee, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir Mohammad BagheriPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Hooriyeh NassirliPharmaceutical Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Shiva GolmohammadzadehDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-5370-6643
Bizhan Malaekeh-NikoueiDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.ORCID https://orcid.org/0000-0002-1908-9530

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Melasma is a persistent skin condition caused by excessive melanin production, particularly affecting women's quality of life. It can result from various factors like sun exposure, genetics, hormones, medications, or inflammation. Effective melasma treatment requires products that can deeply penetrate the skin. The outermost skin layer, known as the stratum corneum (SC), plays a crucial role in delivering topical and transdermal drugs. Researchers have developed numerous strategies to enhance skin permeability and drug efficacy. Methods: This review delves into energy-based techniques and nanocarrier systems for treating melasma, specifically focusing on improving drug delivery to the viable epidermis (EP) while overcoming the SC barrier. Results: Physical methods offer benefits such as enhanced skin penetration but come with drawbacks like frequent visits, high costs, and the need for specialized equipment and skilled operators. Microneedle patches are gaining attention as a convenient physical treatment option for delivering multiple medications effectively, offering targeted delivery and minimal side effects. Nanocarrier systems like transferosomes demonstrate promise in enhancing skin penetration for treating melasma and skin hyperpigmentation. While they offer advantages such as high drug entrapment and improved bioavailability, challenges like stability issues and scalability hinder their widespread adoption. Conclusion: Energy-based techniques enhance drug penetration but can lead to scarring and burns, while dissolvable micro-needles offer a convenient and effective alternative. Nano-drug carriers, like nanostructured lipid carriers (NLCs) and transferosomes, show promise for improved skin drug delivery with their flexible structures and enhanced penetration capabilities, yet further clinical research is needed for definitive conclusions.

Indexed as

Energy-based methodsHyperpigmentationMelasmaNanocarriers

Identifiers

PMID40190686
PMCPMC11970496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.